Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)

  • Post Traumatic Stress Disorder
Trial Status:

Recruiting

This trial runs in
Countries
  • United States
Trial Identifier:

NCT05401565 BN43546

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the efficacy and safety of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults with PTSD.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT05401565 , BN43546 Trial Identifier
      Balovaptan, Placebo Treatments
      Stress Disorders, Post-Traumatic Condition
      Official Title

      A Phase II, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Multicenter Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 60 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants who have a current diagnosis of PTSD as per DSM-5 criteria, with a score of >/=33 on the PCL-5 at screening
      • The index trauma event must have occurred in adulthood, i.e., when the participant was >/=18 years old
      • The index trauma event must have occurred at least 6 months prior to screening and no more than 10 years prior to screening
      • At baseline, either taking a stable dose of a single antidepressant (SSRI or SNRI) for management of PTSD and have been on that medication for >/=6 weeks at that stable dosage and demonstrating residual symptoms of PTSD or prior demonstrated lack of tolerability or lack of efficacy and not taking an antidepressant medication at baseline for >/=6 weeks
      • Treatment with permitted medications and/or non-pharmacological interventions at a stable dose for 6 weeks prior to screening
      • For women of childbearing potential: agreement to remain abstinent or use contraception
      Exclusion Criteria
      • Participants who are experiencing ongoing exposure to traumatic events within 3 months of screening
      • Participants who are pregnant or breastfeeding, or intending to become pregnant during the study or within 14 days after the final dose of study drug
      • Clinically significant psychiatric and/or neurological conditions, which may interfere with the assessment of safety or efficacy endpoints
      • Substance use disorders during last 12 months
      • Significant risk for suicidal behaviour
      • Epilepsy or seizure disorder considered not well controlled within the past 6 months or changes in anticonvulsive therapy within the last 6 months
      • Clinical diagnosis of peripheral neuropathy
      • Within the last 2 years, unstable or clinically significant cardiovascular disorders
      • Positive serology results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) 1 or 2
      • Moderate or severe hepatic or renal impairment
      • History of coagulopathies, bleeding disorders, blood dyscrasias, hematological malignancies, myelosuppression (including iatrogenic)
      • Medical history of malignancy, if not considered cured
      • Participants who have received treatment with investigational therapy within 8 weeks prior to randomization
      • Known hypersensitivity to balovaptan, its components, or any of the excipients used in the formulation

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now